hC Bioscience

Leslie Williams has served as President and CEO since 2022. She joined from Immunovant, where she was COO. Co-founder Michael Koeris remains Executive Chairman. The firm does not disclose a separate investment committee; strategic and pipeline decisions appear to be led by the CEO and the scientific co-founders.

The platform engineers transfer RNA molecules to read through premature stop codons, restoring full-length protein production. Unlike CRISPR or gene replacement therapy, tRNA therapeutics do not modify DNA and operate in the cytoplasm rather than the nucleus. This design aims to avoid permanent genomic changes and reduce the delivery payload requirements that complicate viral vector-based approaches.

The company targets diseases caused by nonsense mutations, where a premature stop codon prevents functional protein expression. Named lead programs include Dravet syndrome, a severe pediatric epilepsy, and cystic fibrosis. The firm has also indicated interest in oncology targets where nonsense mutations contribute to tumor suppression loss.

Yes. hC Bioscience has completed multiple venture financing rounds. Known investors include Arch Venture Partners, Takeda Ventures, and Taiho Ventures, all of whom are specialist biotech investors. Total capital raised has not been publicly disclosed.

hC Bioscience is a venture-backed preclinical biotech company, not a family office. It was co-founded by biotech entrepreneurs Michael Koeris and John Ripple and is headquartered in Cambridge, Massachusetts. No family-office wealth origin or single-family capital base has been disclosed.